Training in HFpEF-PH

Heart Failure With Preserved Ejection Fraction Clinical Trial

— TRAIN HFpEF  

Official title:

Implementation, Safety, Tolerability and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Controlled Multicenter Trial in European Countries.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05464238
• Other study ID #: 2019-04ET
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: December 2026

Study information

• Verified date: September 2022
• Source: Heidelberg University
• Contact: Ekkehard Grünig, MD
• Phone: +496221396
• Email: ekkehard.gruenig[@]med.uni-heidelberg.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved exercise capacity and health-related quality of life. Two meta-analyses have confirmed the beneficial effects in cardiorespiratory fitness and quality of life. The effects of exercise training on systolic and diastolic function remain inconclusive. Due to the positive results of exercise training in HFpEF, cardiac rehabilitation is recommended (Class I, level A) to be integrated into the overall provision of HF care. However, none of these studies focused on concomitant PH in HFpEF. Exercise training in patients with pulmonary hypertension has already shown to improve exercise capacity, quality of life and peak oxygen consumption, which was confirmed by three meta-analyses and a Cochrane review. Though different diagnostic subgroups have already been enrolled in PH exercise training studies, they mainly included pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Data on combined PH and HFpEF is still lacking. As recently pointed out by Arena et al. there may thus be an exercise training volume/intensity which may be detrimental to the RV in patients with HF and concomitant PH. This study is sought to investigate whether a specialized training program is safe and tolerable and may improve exercise capacity, quality of life, hemodynamics, diastolic dysfunction and biomarkers in patients with PH and HFpEF.

Description:

During the 6th World Symposium of PH in Nice, three main entities of PH due to left heart disease (PH-LHD) were identified. 1. PH due to HFpEF, 2. PH due to HF with reduced EF (HFrEF) and 3. PH due to valvular disease. The hemodynamic criteria measured by right heart catheterisation (RHC) of PH-LHD include mean pulmonary arterial pressure (mPAP)>20 mmHg and pulmonary arterial wedge pressure (PAWP) >15 mmHg. The hallmark of HFpEF is an elevation in left-sided filling pressures. In some patients this leads to elevation of mean pulmonary arterial pressure as secondary pulmonary hypertension (PH). Pulmonary arterial pressure is a marker of the severity and chronicity of pulmonary venous congestion in HFpEF and in case of presence of PH, symptoms are more severe and the outcome is poorer. Recently, an updated diagnostic algorithm (HFA-PEFF) for HFpEF was published as consensus recommendation from the Heart Failure Association of the European Society of Cardiology. In first step, a pre-test assessment is performed (P: Pretest). In case risk factors for HFpEF are existing electrocardiographic and echocardiographic evaluation as well as an exercise test are required. If the 1st step is proved positive, a detailed echocardiography (E: echocardiography) should be performed. A definite diagnosis of HFpEF can be made by right heart catheterization with PAWP ≥15mmHg or LVEDP ≥16mmHg at rest and/or PAWP ≥25mmHg during exercise in presence of preserved left ventricular function. Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved exercise capacity and health-related quality of life . Two meta-analyses have confirmed the beneficial effects in cardiorespiratory fitness and quality of life. The effects of exercise training on systolic and diastolic function remain inconclusive. Due to the positive results of exercise training in HFpEF, cardiac rehabilitation is recommended (Class I, level A) to be integrated into the overall provision of HF care. However, none of these studies focused on concomitant PH in HFpEF. Exercise training in patients with pulmonary hypertension has already shown to improve exercise capacity, quality of life and peak oxygen consumption, which was confirmed by three meta-analyses and a Cochrane review. Though different diagnostic subgroups have already been enrolled in PH exercise training studies, they mainly included pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Data on combined PH and HFpEF is still lacking. In healthy subjects, intensive exercise has already shown to cause potentially deleterious remodeling of the RV. As recently pointed out by Arena et al. there may thus be an exercise training volume/intensity which may be detrimental to the RV in patients with HF and concomitant PH. This study is sought to investigate whether a specialized training program is safe and tolerable and may improve exercise capacity, quality of life, hemodynamics, diastolic dysfunction and biomarkers in patients with PH and HFpEF.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female and male patients =18 years

2. WHO/NYHA functional class II - IV

3. PH with HFpEF diagnosed by right heart catheterisation showing:

mean pulmonary arterial pressure (mPAP) =25mmHg at rest; pulmonary arterial wedge pressure (PAWP) =15mmHg at rest or LVEDP =16mmHg and/or PAWP=25 mmHg during exercise, and

4. Preserved left ventricular ejection fraction =50%

5. Patients receiving optimized therapy including intensified treatment with diuretics and who have been stable for 1 month before entering the study.

6. Except for diuretics, medical treatment should not be changed during the study period.

7. Able to understand and willing to sign the Informed Consent Form

Exclusion Criteria:

1. Pre-capillary pulmonary hypertension (Group I; Group III; Group IV; Group V according to PH guidelines)

2. Congenital or acquired severe valvular diseases (severe aortic stenosis or insufficiency, severe mitral valve stenosis or insufficiency)

3. Pregnancy or lactation

4. Walking disability

5. Subject who participates in an interventional study during the course of this study

6. Severe lung disease: FEV1/FVC <0.5 and total lung capacity <60% of the normal value

7. Active myocarditis, unstable angina pectoris, exercise induced ventricular arrhythmias, active liver disease, porphyria or elevations of serum transaminases >3 x ULN (upper limit of normal) or bilirubin >1.5 x ULN

8. Haemoglobin concentration less than 75% of the lower limit of normal

9. Systolic blood pressure <85 mmHg

10. History or suspicion of inability to cooperate adequately.

Related Conditions & MeSH terms

• Heart Diseases
• Heart Failure
• Heart Failure With Preserved Ejection Fraction
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension Due to Left Heart Disease

Intervention

Other:
• Exercise rehabilitation
The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
• Standard treatment
Standard treatment during study duration

Locations

Country	Name	City	State
Germany	Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital	Heidelberg
Lithuania	Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania	Vilnius

Sponsors (1)

Lead Sponsor	Collaborator
Heidelberg University

Countries where clinical trial is conducted

Germany,  Lithuania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-minute walking distance		baseline to 15 weeks
Secondary	WHO functional class		baseline to 15 weeks
Secondary	Quality of life physical component scale SF-36		baseline to 15 weeks
Secondary	Quality of life mental component scale SF-36		baseline to 15 weeks
Secondary	peak oxygen consumption		baseline to 15 weeks
Secondary	peak oxygen consumption/kg body weight		baseline to 15 weeks
Secondary	workload achieved during cardiopulmonary exercise testing		baseline to 15 weeks
Secondary	NT-proBNP (N-terminal pro brain natriuretic peptide)		baseline to 15 weeks
Secondary	Tricuspid annular plane systolic excursion	echocardiography	baseline to 15 weeks
Secondary	Systolic pulmonary arterial pressure	echocardiography	baseline to 15 weeks
Secondary	Right atrial area	echocardiography	baseline to 15 weeks
Secondary	Right ventricular area	echocardiography	baseline to 15 weeks
Secondary	Right ventricular pump function	echocardiography	baseline to 15 weeks
Secondary	Left ventricular pump function	echocardiography	baseline to 15 weeks
Secondary	Left ventricular eccentricity index	echocardiography	baseline to 15 weeks